
Home » TOYAMA LAUNCHES TRIALS OF ANTIRHEUMATIC AGENT
TOYAMA LAUNCHES TRIALS OF ANTIRHEUMATIC AGENT
Toyama Chemical has begun Phase I clinical trials of T-5224, its proprietary drug candidate for the treatment of rheumatoid arthritis (RA).
A low-molecular compound that inhibits an activator protein 1 (AP-1), T-5224 alleviates inflammation and joint destruction so it is expected to be used as a basic remedy for RA.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
13Jul
-
27Jul
-
28Jul
-
28Jul
-
02Aug
-
03Aug